Long-Acting Drug Delivery Technologies & Services Market - Distribution by Principle, Strategy, Compatible Dosage Form, Type of Molecule Delivered, Type of Material Used, & Key Geographical Regions: Industry Trends & Global Forecasts, 2023-2035

Long-acting drug delivery is an innovative drug delivery approach which allows sustained action of a drug for weeks, months or years after single administration and maintains its optimal therapeutic level in the patient's body. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. The long-acting delivery of drug candidates confers several advantages, such as improved patient compliance, reduced dosage requirement, better medication adherence, decrease in failure risk due to inconsistent usage and more convenience to patients. Of late, the demand for the availability of long-acting vaginal rings as multipurpose prevention technologies for women is also surfacing. It is worth mentioning that a suitable combination of dosage form (long-acting implants, injectables, vaginal, oral and topical / transdermal dosage forms) and strategy (micro-encapsulation, nanocrystal suspensions, long-acting hydrogels and microneedles) enables better biodistribution and exertion of a localized therapeutic action of the drug for an extended duration. Driven by the ongoing pace of innovation in the formulation of these technologies and the increasing demand for long-acting drugs, the long-acting drug delivery market is anticipated to witness substantial growth in the foreseen future.

SCOPE OF THE REPORT

The "Long-Acting Drug Delivery Technologies and Services Market, 2023-2035: Distribution by Principle (Manipulation of drug release from delivery systems and Manipulation of in vivo clearance), Strategy (Chemical Modification, Micro-encapsulation, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, Multivesicular Liposomes, Nanocrystal Suspensions and Protein Fusion), Compatible Dosage Form (Injectables, Implantables, Oral, Topical / Transdermal, Vaginal and Other Dosage Forms), Type of Molecule Delivered (Small Molecules, Biologics and Other Molecules), Type of Material Used (Polymer based and Non-polymer based), and Key Geographical Regions (North America, Europe, Asia-Pacific and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035" report features an extensive study of the current technologies and service providers landscape and the likely future potential of the long-acting drug delivery technologies and services market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. The report answers the following key questions related to this domain.

What are the Benefits of Long-Acting Delivery of the Drugs?

The standard-of-care treatment options for several diseases, such as schizophrenia, Alzheimer's disease, age-related macular degeneration, HIV prophylaxis, can be bothersome for patients because of regular intake of the prescribed medication. Patient non-compliance can further worsen the disease, where the medication is anticipated to be consumed for several months to years. In order to circumvent the high rate of non-compliance and non-adherence, long-acting drug delivery has been considered as a novel pharmacologic strategy. This delivery enables the continuous administration of active pharmaceutical ingredients (biologics, small molecules and peptides) for extended time period (weeks, months or years) after a single dose. The technological advancements in the field of long-acting drug delivery ascertain therapeutic efficacy, safety and improved drug pharmacokinetic and pharmacodynamic profiles. It is worth highlighting that, in 2021, the United States Food and Drug Administration (USFDA) approved Cabotegravir, the first long-acting injectable for the treatment of human immunodeficiency virus (HIV) pre-exposure prophylaxis, with the dosing regimen of once every two months.

What is the Current Landscape of the Long-Acting Drug Delivery Technologies?

Currently, more than 100 long-acting drug delivery technologies are available / being developed by various industry stakeholders for the treatment of multiple diseases. The design of these technologies is based on either of the two principles, manipulation of drug release from delivery systems or manipulation of in vivo clearance. Amongst the strategies which allow the long-lasting effect, over 30% of the long-acting drug delivery technologies are suitable for long-acting implants / devices. It is worth mentioning that 70% of the technologies are compatible with injectables (depot and long-acting injections).

What is the Need for Outsourcing Long-Acting Drug Development and Manufacturing Services to Contract Service Providers?

The development and manufacturing of these complex drug products requires great technical skill and scientific expertise. One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Also, scale-up and regulatory filing for a less-defined regulatory pathway often appear as a bottleneck in the clinical and commercial translation of these drugs. In order to mitigate these technical and operational complexities, pharmaceutical companies tend to outsource their operations to the players that offer services for the development and manufacturing of long-acting drugs.

What are the Key Trends in the Long-Acting Drug Delivery Technologies and Services Market?

Many stakeholders have been making consolidated efforts to forge alliance with other industry / non-industry players for technology licensing, product development and manufacturing purposes. It is worth highlighting that over 90 strategic partnerships have been inked since 2018 in this domain. Additionally, in the same time frame, more than 1,200 patents related to long-acting drug delivery have been filed / granted, highlighting the continuous pace of innovation in this field. Moreover, the field is evolving continuously, as researchers and industry players aim to enhance the existing technologies and delivery systems. In this context, in the past three years, over 360 long-acting drug delivery focused articles have been published. Given the inclination towards cutting-edge long-acting technologies, along with innovative approaches to tailor the dosing regimen, we believe that the long-acting drug delivery technologies and services market is likely to evolve at a rapid pace, over the coming years.

What is the Market Size of Long-Acting Drug Delivery Technologies and Services Market?

Lately, the pharmaceutical industry has witnessed the development of advanced long-acting drug delivery technology platforms. This is due to the ability of long-acting drugs to obviate the concerns associated with conventional treatment options. Eventually, these patient-centric treatment modalities aid in the reduction of treatment burden and need for surgical intervention. The global long-acting drug delivery technologies and services market is projected to grow at a CAGR of ~13% and ~11%, respectively, in the period 2023-2035. Further, in 2035, the long-acting drug delivery technologies market for micro-encapsulation is expected to capture the majority share. In terms of geography, the long-acting drug delivery services market in North America and Europe is anticipated to grow at a relatively faster pace by 2035.

Who are the Key Players in the Long-Acting Drug Delivery Technologies and Services Market?

Examples of key players engaged in the long-acting drug delivery technology domain (which have also been captured in this report) include 3-D Matrix, Alnylam Pharmaceuticals, Amorphex Therapeutics, Bostal Drug Delivery, Cipla, Delpor, Heron Therapeutics and Nanexa.

In addition, examples of key players offering long-acting drug delivery services (which have also been captured in this report) include Ascendia Pharmaceuticals, Caplin Steriles, Evonik, Indoco Remedies, Phosphorex and TTY Biopharm.

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report features:

An executive summary of the insights captured during our research. It offers a high-level view on the current state of long-acting drug delivery technologies and services market and its likely evolution in the mid-long term.
A general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.
A detailed assessment of the current technology landscape of long-acting drug delivery technologies, based on several relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), type of material used (polymer based and non-polymer based), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), extended dosing interval(s) (weeks, months and years), type of molecule(s) delivered (biologics, small molecules and other molecules), highest phase of development (preclinical, clinical and approved), number of approved drugs and therapeutic area(s) (oncological disorders, ophthalmological disorders, neurological disorders, opioid use disorders / pain, women health, metabolic disorders, infectious diseases, cardiovascular disorders, autoimmune disorders, immunological disorders and others). In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, such as their year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).
A detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s) (contract development organization, contract manufacturing organization and contract development and manufacturing organization), scale of operation (preclinical, clinical and commercial), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), service(s) offered (product development, process development / pre-formulation, analytical method development, formulation development, manufacturing, technology transfer, stability studies, feasibility studies, scale-up, regulatory support and others) and type of molecule(s) supported (biologics, small molecules and other molecules).
A technology competitiveness analysis of long-acting drug delivery technologies based on developer power (in terms of the experience of the developer) and technology strength (in terms of principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development and therapeutic area(s)).
A company competitiveness analysis of long-acting drug delivery service providers based on company strength (in terms of years of experience and company size) and service strength (in terms of number of technology platform(s), type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported).
Elaborate profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery, located across North America, Europe and Asia-Pacific (shortlisted based on a proprietary criterion). Each profile features a brief overview of the company, details related to its technology portfolio, service portfolio, recent developments and an informed future outlook.
A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.
A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long-acting drug delivery, based on several relevant parameters, such as year of publication, type of publication and popular keywords. The chapter also highlights the top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).
An in-depth analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, the chapter includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).
A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, type of grant application, purpose of grant award, activity code, NIH spending category, study section involved, popular NIH departments (in terms of number of grants) and type of recipient organization. Further, the chapter also highlights the prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants and amount awarded).

One of the key objectives of the report was to evaluate the current opportunity and future potential associated with long-acting drug delivery technologies and services market, over the coming 12 years. We have provided informed estimates of the likely evolution of the market in the short to mid-term and long term, for the period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), compatible dosage form (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), type of molecule delivered (small molecules, biologics and other molecules), type of material used (polymer based and non-polymer based) and key geographical regions (North America, Europe, Asia-Pacific and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in the report were influenced by discussions held with stakeholders in this domain. The report features detailed transcript of interview held with the industry stakeholders.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent views on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED

Question 1: What are the major factors driving the long-acting drug delivery technologies and services market?

Answer: The need for improved patient convenience and compliance, medication adherence, lower dosage requirement for the treatment of several diseases, especially chronic diseases, has accentuated the demand for long-acting drug delivery formulations.

Question 2: How many long-acting drug delivery technologies, compatible with long-acting injectables, are available in the market?

Answer: Presently, more than 80 technologies available in the market are compatible with long-acting injectables.

Question 3: How many long-acting drug delivery technologies demonstrate extended dosage regimen of at least a year?

Answer: Close to 20 technologies support the development of long-acting injectables, long-acting implants and vaginal rings with superior dosing regimen of a year and above.

Question 4: What percent of the total contract service providers are offering both product development and manufacturing of long-acting drugs?

Answer: Close to 40% of the players involved in this domain claim to offer product development and manufacturing of long-acting drugs; notable examples include InnoCore Pharmaceuticals, Lubrizol Life Science Health, Mithra Pharmaceuticals, Pensatech Pharma.

Question 5: How many contract service providers possess technology transfer capabilities related to long-acting drug delivery?

Answer: Nearly 50% of the contract service providers engaged in this domain claim to have the requisite capabilities to aid in technology transfer of long-acting drug delivery technologies for the development of the long-acting drugs.

Question 6: What are the partnership and collaboration trends in the long-acting drug delivery domain?

Answer: Currently, product development agreements, technology licensing agreements and acquisitions are the most common types of partnerships inked by stakeholders in the long-acting drug delivery domain.

Question 7: What is the current patent landscape of long-acting drug delivery market?

Answer: 656 patents filed in this domain are patent applications, while 571 are granted patents. Of the total granted applications, close to 85% patents were filed in the US.

Question 8: Which segment, in terms of strategies, accounts for the largest share in the global long-acting drug delivery technologies market?

Answer: Presently, micro-encapsulation strategy accounts for the largest share (close to 50%) of the global long-acting drug delivery technologies market. However, strategies, such as long-acting microneedles, multivesicular liposomes and long-acting hydrogels are likely to witness higher annual growth rates in the upcoming years. This can be attributed to the rising demand for such promising and versatile drug delivery-based technologies, characterized by distinct physical properties.

Question 9: Which geography is expected to witness the highest growth rate in the long-acting drug delivery services market?

Answer: The long-acting drug delivery services market in Europe is likely to grow at the highest CAGR, during the period 2023- 2035.

CHAPTER OUTLINES

Chapter 1: is a preface providing an introduction to the full report, Long-acting drug delivery technologies and services market, 2023-2035.

Chapter 2: provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of long-acting drug delivery technologies and services market and its likely evolution in the mid-long term.

Chapter 3: provides a general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery.

Chapter 4: includes detailed assessment of the current technology landscape of long-acting drug delivery technologies, based on several relevant parameters, such as principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), type of material used (polymer based and non-polymer based), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), extended dosing interval(s) (weeks, months and years), type of molecule(s) delivered (biologics, small molecules and other molecules), highest phase of development (preclinical, clinical and approved), number of approved drugs and therapeutic area(s) (oncological disorders, ophthalmological disorders, neurological disorders, opioid use disorders / pain, women health, metabolic disorders, infectious diseases, cardiovascular disorders, autoimmune disorders, immunological disorders and others). In addition, the chapter features information on various technology developers, along with analysis based on multiple parameters, such as their year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).

Chapter 5: includes detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s) (contract development organization, contract manufacturing organization and contract development and manufacturing organization), scale of operation (preclinical, clinical and commercial), compatible dosage form(s) (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), service(s) offered (product development, process development / pre-formulation, analytical method development, formulation development, manufacturing, technology transfer, stability studies, feasibility studies, scale-up, regulatory support and others) and type of molecule(s) supported (biologics, small molecules and other molecules).

Chapter 6: presents a detailed technology competitiveness analysis of long-acting drug delivery technologies based on developer power (in terms of the experience of the developer) and technology strength (in terms of principle, strategy, type of material used, compatible dosage form(s), extended dosing interval(s), type of molecule(s) delivered, highest phase of development and therapeutic area(s)).

Chapter 7: presents a detailed company competitiveness analysis of long-acting drug delivery service providers based on company strength (in terms of years of experience and company size) and service strength (in terms of number of technology platform(s), type of service provider(s), scale of operation, compatible dosage form(s), service(s) offered and type of molecule(s) supported).

Chapter 8: features detailed profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery, located across North America, Europe and Asia-Pacific (shortlisted based on a proprietary criterion). Each profile features a brief overview of the company, details related to its technology portfolio, service portfolio, recent developments and an informed future outlook.

Chapter 9: features a detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018, covering acquisitions, manufacturing agreements, product development and commercialization agreements, service alliance, technology licensing agreements, and other relevant agreements.

Chapter 10: provides a detailed analysis of over 570 peer-reviewed, scientific articles on research related to long-acting drug delivery, based on several relevant parameters, such as year of publication, type of publication and popular keywords. The chapter also highlights the top journals, top publishers, top copyright holders and key funding institutes (in terms of number of articles published).

Chapter 11: features an insightful analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018, taking into consideration parameters, such as publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. In addition, it also includes a detailed patent benchmarking and an insightful valuation analysis, highlighting the leading patents (in terms of number of citations).

Chapter 12: provides a detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018, based on several parameters, such as year of grant award, amount awarded, support period, type of funding institute center, grant application, purpose of grant award, grant activity code, NIH spending category, study section involved, popular NIH departments (in terms of number of grants) and type of recipient organization. Further, it also highlights the prominent program officers (in terms of number of grants) and popular recipient organizations (in terms of number of grants and amount awarded).

Chapter 13: presents a comprehensive market forecast and opportunity analysis, highlighting the future potential of the market till the year 2035. We have segregated the current and upcoming opportunity based on principle (manipulation of drug release from delivery systems and manipulation of in vivo clearance), strategy (chemical modification, micro-encapsulation, long-acting hydrogels, long-acting implants, long-acting microneedles, multivesicular liposomes, nanocrystal suspensions and protein fusion), compatible dosage form (injectables, implantables, oral, topical / transdermal, vaginal and other dosage forms), type of molecule delivered (small molecules, biologics and other molecules), type of material used (polymer based and non-polymer based) and key geographical regions (North America, Europe, Asia-Pacific and Middle East and North Africa).

Chapter 14: summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15: provides the transcripts of interviews conducted with key stakeholders in this industry.

Chapter 16: is an appendix, which contains tabulated data and numbers for all the figures included in the report.

Chapter 17: is an appendix, which contains a list of companies and organizations mentioned in this report.

Product Code: RA100410

1. PREFACE

1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Overview of Long-Acting Drug Delivery
- 3.2.1. Types of Long-Acting Drug Delivery Systems
3.3. Long-Acting Drug Delivery Technologies
- 3.3.1. Underlying Principle
- 3.3.2. Associated Strategies
3.4. Concluding Remarks

4. TECHNOLOGY LANDSCAPE

4.1. Chapter Overview
4.2. Long-Acting Drug Delivery: Technology Landscape
- 4.2.1. Analysis by Principle
- 4.2.2. Analysis by Strategy
- 4.2.3. Analysis by Type of Material Used
- 4.2.4. Analysis by Compatible Dosage Form(s)
- 4.2.5. Analysis by Extended Dosing Interval(s)
- 4.2.6. Analysis by Type of Molecule(s) Delivered
- 4.2.7. Analysis by Highest Phase of Development
- 4.2.8. Analysis by Number of Approved Drugs
- 4.2.9. Analysis by Therapeutic Area(s)
4.3. Long-Acting Drug Delivery: Technology Developers Landscape
- 4.3.1. Analysis by Year of Establishment
- 4.3.2. Analysis by Company Size
- 4.3.3. Analysis by Location of Headquarters
- 4.3.4. Most Active Players: Analysis by Number of Technologies

5. SERVICE PROVIDERS LANDSCAPE

5.1. Chapter Overview
5.2. Long-Acting Drug Delivery: Service Providers Landscape
- 5.2.1. Analysis by Year of Establishment
- 5.2.2. Analysis by Company Size
- 5.2.3. Analysis by Location of Headquarters
- 5.2.4. Analysis by Company Size and Location of Headquarters
- 5.2.5. Analysis by Location of Facilities
- 5.2.6. Analysis by Type of Service Provider(s)
- 5.2.7. Analysis by Scale of Operation
- 5.2.8. Analysis by Compatible Dosage Form(s)
- 5.2.9. Analysis by Scale of Operation and Compatible Dosage Form(s)
- 5.2.10. Analysis by Service(s) Offered
- 5.2.11. Analysis by Company Size and Service(s) Offered
- 5.2.12. Analysis by Year of Establishment, Location of Headquarters and Service(s) Offered
- 5.2.13. Analysis by Type of Molecule(s) Supported
- 5.2.14. Analysis by Type of Service Provider(s) and Type of Molecule(s) Supported

6. TECHNOLOGY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions / Key Parameters
6.3. Methodology
6.4. Technology Competitiveness Analysis
- 6.4.1. Long-Acting Drug Delivery Technologies offered by Small Companies
- 6.4.2. Long-Acting Drug Delivery Technologies offered by Mid-sized Companies
- 6.4.3. Long-Acting Drug Delivery Technologies offered by Large Companies
- 6.4.4. Long-Acting Drug Delivery Technologies offered by Very Large Companies

7. COMPANY COMPETITIVENESS ANALYSIS

7.1. Chapter Overview
7.2. Assumptions / Key Parameters
7.3. Methodology
7.4. Company Competitiveness Analysis
- 7.4.1. Long-Acting Drug Delivery Service Providers based in North America
- 7.4.2. Long-Acting Drug Delivery Service Providers based in Europe
- 7.4.3. Long-Acting Drug Delivery Service Providers based in Asia-Pacific

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Adare Pharma Solutions
- 8.2.1. Company Overview
- 8.2.2. Technology Portfolio
- 8.2.3. Service Portfolio
- 8.2.4. Recent Developments and Future Outlook
8.3. AMW
- 8.3.1. Company Overview
- 8.3.2. Technology Portfolio
- 8.3.3. Service Portfolio
- 8.3.4. Recent Developments and Future Outlook
8.4. Bostal Drug Delivery
- 8.4.1. Company Overview
- 8.4.2. Technology Portfolio
- 8.4.3. Service Portfolio
- 8.4.4. Recent Developments and Future Outlook
8.5. Creative Biolabs
- 8.5.1. Company Overview
- 8.5.2. Technology Portfolio
- 8.5.3. Service Portfolio
- 8.5.4. Recent Developments and Future Outlook
8.6. ForDoz Pharma
- 8.6.1. Company Overview
- 8.6.2. Technology Portfolio
- 8.6.3. Service Portfolio
- 8.6.4. Recent Developments and Future Outlook
8.7. InnoCore Pharmaceuticals
- 8.7.1. Company Overview
- 8.7.2. Technology Portfolio
- 8.7.3. Service Portfolio
- 8.7.4. Recent Developments and Future Outlook
8.8. Integral BioSystems
- 8.8.1. Company Overview
- 8.8.2. Technology Portfolio
- 8.8.3. Service Portfolio
- 8.8.4. Recent Developments and Future Outlook
8.9. LATITUDE Pharmaceuticals
- 8.9.1. Company Overview
- 8.9.2. Technology Portfolio
- 8.9.3. Service Portfolio
- 8.9.4. Recent Developments and Future Outlook
8.10. Navin Saxena Research and Technology Centre (NSRT)
- 8.10.1. Company Overview
- 8.10.2. Technology Portfolio
- 8.10.3. Service Portfolio
- 8.10.4. Recent Developments and Future Outlook
8.11. Samyang Biopharm
- 8.11.1. Company Overview
- 8.11.2. Technology Portfolio
- 8.11.3. Service Portfolio
- 8.11.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

9.1. Chapter Overview
9.2. Partnership Models
9.3. Long-Acting Drug Delivery Technologies and Services: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Location of Headquarters of Partner
- 9.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
- 9.3.7. Most Active Players: Analysis by Number of Partnerships
- 9.3.8. Regional Analysis
  - 9.3.8.1. Intercontinental and Intracontinental Deals
  - 9.3.8.2. Local and International Deals

10. PUBLICATION ANALYSIS

10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Long-Acting Drug Delivery: Publication Analysis
- 10.3.1. Analysis by Year of Publication
- 10.3.2. Analysis by Type of Publication
- 10.3.3. Analysis by Most Popular Keywords
- 10.3.4. Most Popular Journals: Analysis by Number of Publications
- 10.3.5. Most Popular Publishers: Analysis by Number of Publications
- 10.3.6. Most Popular Copyright Holders: Analysis by Number of Publications
- 10.3.7. Key Funding Institutes: Analysis by Number of Publications

11. PATENT ANALYSIS

11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Long-Acting Drug Delivery: Patent Analysis
- 11.3.1. Analysis by Publication Year
- 11.3.2. Analysis by Type of Patent and Publication Year
- 11.3.3. Analysis by Geography
- 11.3.4. Analysis by CPC Symbols
- 11.3.5. Leading Industry Players: Analysis by Number of Patents
- 11.3.6. Analysis by Type of Organization
11.4. Patent Benchmark Analysis
- 11.4.1. Analysis by Patent Characteristics
11.5. Patent Valuation Analysis

12. GRANT ANALYSIS

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Long-Acting Drug Delivery: Grant Analysis
- 12.3.1. Analysis by Year of Grant Award
- 12.3.2. Analysis by Amount Awarded
- 12.3.3. Analysis by Support Period
- 12.3.4. Analysis by Support Period and Funding Institute Center
- 12.3.5. Analysis by Type of Grant Application
- 12.3.6. Analysis by Purpose of Grant Award
- 12.3.7. Analysis By Activity Code
- 12.3.8. Analysis by NIH Spending Category
- 12.3.9. Analysis by Study Section Involved
- 12.3.10. Popular NIH Departments: Analysis by Number of Grants
- 12.3.11. Analysis by Type of Recipient Organization
- 12.3.12. Prominent Program Officers: Analysis by Number of Grants
- 12.3.13. Popular Recipient Organizations: Analysis by Number of Grants
- 12.3.14. Popular Recipient Organizations: Analysis by Grant Amount
- 12.3.15. Analysis by Region of Recipient Organizations

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Long-Acting Drug Delivery Technologies Market, 2023-2035
- 13.3.1. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Payment Model Employed
  - 13.3.1.1. Long-Acting Drug Delivery Technologies Market for Upfront Payment, 2023-2035
  - 13.3.1.2. Long-Acting Drug Delivery Technologies Market for Milestone Payment, 2023-2035
- 13.3.2. Long-Acting Drug Delivery Technologies Market: Analysis by Principle
  - 13.3.2.1. Long-Acting Drug Delivery Technologies Market for Manipulation of Drug Release from Delivery Systems, 2023-2035
  - 13.3.2.2. Long-Acting Drug Delivery Technologies Market for Manipulation of In Vivo Clearance, 2023-2035
- 13.3.3. Long-Acting Drug Delivery Technologies Market: Analysis by Strategy
  - 13.3.3.1. Long-Acting Drug Delivery Technologies Market for Micro-encapsulation, 2023-2035
  - 13.3.3.2. Long-Acting Drug Delivery Technologies Market for Long-Acting Implants, 2023-2035
  - 13.3.3.3. Long-Acting Drug Delivery Technologies Market for Multivesicular Liposomes, 2023-2035
  - 13.3.3.4. Long-Acting Drug Delivery Technologies Market for Nanocrystal Suspensions, 2023-2035
  - 13.3.3.5. Long-Acting Drug Delivery Technologies Market for Long-Acting Hydrogels, 2023-2035
  - 13.3.3.6. Long-Acting Drug Delivery Technologies Market for Long-Acting Microneedles, 2023-2035
  - 13.3.3.7. Long-Acting Drug Delivery Technologies Market for Chemical Modification, 2023-2035
  - 13.3.3.8. Long-Acting Drug Delivery Technologies Market for Protein Fusion, 2023-2035
- 13.3.4. Long-Acting Drug Delivery Technologies Market: Analysis by Compatible Dosage Form
  - 13.3.4.1. Long-Acting Drug Delivery Technologies Market for Injectables, 2023-2035
  - 13.3.4.2. Long-Acting Drug Delivery Technologies Market for Implantables, 2023-2035
  - 13.3.4.3. Long-Acting Drug Delivery Technologies Market for Vaginal Dosage Forms, 2023-2035
  - 13.3.4.4. Long-Acting Drug Delivery Technologies Market for Topical / Transdermal Dosage Forms, 2023-2035
  - 13.3.4.5. Long-Acting Drug Delivery Technologies Market for Oral Dosage Forms, 2023-2035
  - 13.3.4.6. Long-Acting Drug Delivery Technologies Market for Other Dosage Forms, 2023-2035
- 13.3.5. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Molecule Delivered
  - 13.3.5.1. Long-Acting Drug Delivery Technologies Market for Small Molecules, 2023-2035
  - 13.3.5.2. Long-Acting Drug Delivery Technologies Market for Biologics, 2023-2035
  - 13.3.5.3. Long-Acting Drug Delivery Technologies Market for Other Molecules, 2023-2035
- 13.3.6. Long-Acting Drug Delivery Technologies Market: Analysis by Type of Material Used
  - 13.3.6.1. Long-Acting Drug Delivery Technologies Market for Polymer-based, 2023-2035
  - 13.3.6.2. Long-Acting Drug Delivery Technologies Market for Non-polymer based, 2023-2035
- 13.3.7. Long-Acting Drug Delivery Technologies Market: Analysis by Region
  - 13.3.7.1. Long-Acting Drug Delivery Technologies Market in North America, 2023-2035
  - 13.3.7.2. Long-Acting Drug Delivery Technologies Market in Europe, 2023-2035
  - 13.3.7.3. Long-Acting Drug Delivery Technologies Market in Asia-Pacific, 2023-2035
  - 13.3.7.4. Long-Acting Drug Delivery Technologies Market in Middle East and North Africa, 2023-2035
13.4. Global Long-Acting Drug Delivery Services Market, 2023-2035
- 13.4.1. Long-Acting Drug Delivery Services Market: Analysis by Compatible Dosage Form
  - 13.4.1.1. Long-Acting Drug Delivery Services Market for Injectables, 2023-2035
  - 13.4.1.2. Long-Acting Drug Delivery Services Market for Implantables, 2023-2035
  - 13.4.1.3. Long-Acting Drug Delivery Services Market for Vaginal Dosage Forms, 2023-2035
  - 13.4.1.4. Long-Acting Drug Delivery Services Market for Topical / Transdermal Dosage Forms, 2023-2035
  - 13.4.1.5. Long-Acting Drug Delivery Services Market for Oral Dosage Forms, 2023-2035
  - 13.4.1.6. Long-Acting Drug Delivery Services Market for Other Dosage Forms, 2023-2035
- 13.4.2. Long-Acting Drug Delivery Services Market: Analysis by Type of Molecule Supported
  - 13.4.2.1. Long-Acting Drug Delivery Services Market for Small Molecules, 2023-2035
  - 13.4.2.2. Long-Acting Drug Delivery Services Market for Biologics, 2023-2035
  - 13.4.2.3. Long-Acting Drug Delivery Services Market for Other Molecules, 2023-2035
- 13.4.3. Long-Acting Drug Delivery Services Market: Analysis by Region
  - 13.4.3.1. Long-Acting Drug Delivery Services Market in North America, 2023-2035
  - 13.4.3.2. Long-Acting Drug Delivery Services Market in Europe, 2023-2035
  - 13.4.3.3. Long-Acting Drug Delivery Services Market in Asia-Pacific, 2023-2035

14. CONCLUSION

15. INTERVIEW TRANSCRIPTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS